Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

35.3%

6 terminated/withdrawn out of 17 trials

Success Rate

64.7%

-21.8% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

91%

10 of 11 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

Phase 1

10(58.8%)

Phase 2

6(35.3%)

Phase 3

1(5.9%)

17Total

Phase 1(10)

Phase 2(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT04672434Phase 1Completed

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Role: lead

NCT04641871Phase 1Completed

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Role: lead

NCT03311412Phase 1Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Role: lead

NCT02648724Phase 1Completed

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

Role: lead

NCT03489343Phase 1Completed

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Role: lead

NCT03489369Phase 1Completed

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Role: lead

NCT03549338Phase 2Terminated

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Role: lead

NCT02906670Phase 1Terminated

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

Role: lead

NCT02540161Phase 2Completed

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

Role: collaborator

NCT02083653Phase 2Completed

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Role: lead

NCT02568046Phase 1Terminated

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Role: lead

NCT03717038Phase 3Withdrawn

Sym004 Versus TAS-102 in Patients With mCRC

Role: lead

NCT00718692Phase 2Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Role: lead

NCT01417936Phase 2Completed

Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Role: lead

NCT01117428Phase 1Completed

Sym004 in Patients With Advanced Solid Tumors

Role: lead

NCT02924233Phase 1Withdrawn

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Role: lead

NCT02965417Phase 2Withdrawn

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Role: lead

All 17 trials loaded